Press Release

HIV RT Inhibitor Azvudine Received IND Approval

Zhengzhou, China – May 18, 2013, Zhengzhou Granlen PharmaTech Ltd, a Division of Granlen LLC in San Diego, California, USA, announced today the HIV RT inhibitor Azvudine, accomplished by Granlen and collaborators, received Investigational New Drug (IND) approval on April 30, 2013 from SFDA for clinical studies.

“We are extremely pleased for the IND approval granted by SFDA for clinical studies of Azvudine. This accomplishment established the solid base for us to serve our global clients more efficiently.” Said Harry An, Ph. D., Founder and President, Granlen. “We will continue to work closely with regulatory authorities and our partners to fulfill the clinical investigation needs and bring this important new therapy to market.”

About Granlen – “The Reliability”

Granlen is a global contract research organization (CRO) to provide reliable chemistry, drug discovery and development related services for biotech, pharmaceutical, cosmaceutical, and related industries with a broad spectrum of chemistry, a wide range of drug discovery services, and an integrated drug development process to IND. The highly experienced team in multi-disciplinary areas is committed to exceeding clients’ expectations and becoming your partner of choice. Therefore, Granlen is cable of providing high quality, reliable and cost-effective chemistry-driven drug discovery and development services.

Forward-Looking Statement

This press release may contain forward-looking statements that are subject to risks, uncertainties and other factors. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. All forward-looking statements are based on information currently available to Granlen, and Granlen assumes no obligation to update any such forward-looking statements.

For more information on Granlen, please visit the company’s website at www.granlen.com or send inquiry to info@granlen.com, or contact:

philip.fang, philip.fang@granlen.com; +86-371-85513397

Zhengzhou Granlen PharmaTech Ltd., a Division of Granlen

7864 Paseo Tulipero, Carlsbad, CA 92009, USA